Welcome to our dedicated page for Adagene news (Ticker: ADAG), a resource for investors and traders seeking the latest updates and insights on Adagene stock.
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company focused on antibody-based cancer immunotherapies, and its news flow reflects ongoing clinical, regulatory, scientific, and partnering activity. The company reports that it combines computational biology and artificial intelligence within its Dynamic Precision Library platform, which includes NEObody, SAFEbody, and POWERbody technologies, to design novel antibodies for oncology.
News about Adagene frequently centers on its lead program, ADG126 (muzastotug), a masked, anti-CTLA-4 SAFEbody targeting regulatory T cells in the tumor microenvironment. Recent announcements have covered Phase 1b/2 data in metastatic microsatellite-stable colorectal cancer without liver metastases, initiation of a randomized Phase 2 dose optimization study in combination with pembrolizumab, and the FDA’s Fast Track Designation for muzastotug plus pembrolizumab in a defined MSS metastatic colorectal cancer population. Regulatory updates, such as outcomes from a Type B (End of Phase 1) meeting with the FDA and alignment on Phase 2 and Phase 3 trial designs and endpoints, are also key elements of the company’s news.
Adagene’s press releases additionally highlight strategic collaborations and transactions. Examples include a strategic investment and clinical collaboration with Sanofi to support development of ADG126 and additional SAFEbody discovery programs, an expanded collaboration with Exelixis to develop masked antibody-drug conjugates, a licensing agreement with Third Arc Bio for masked CD3 T cell engagers, and a partnership with ConjugateBio to provide a proprietary antibody for bispecific ADC development. Corporate updates, participation in investor conferences, and leadership appointments in immuno-oncology are also part of the company’s public communications.
Investors and observers following ADAG news can expect coverage of clinical trial progress for ADG126, regulatory milestones, data presentations at scientific meetings, and developments in Adagene’s collaborations that leverage its SAFEbody precision masking technology and Dynamic Precision Library platform.
Adagene Inc. (Nasdaq: ADAG) will participate in one-on-one investor meetings and provide a corporate update at the SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022. The presentation is scheduled for February 17 at 11:20 a.m. ET. Investors can access a webcast of the presentation on Adagene's website for 30 days. Adagene focuses on developing novel antibody-based cancer immunotherapies utilizing its Dynamic Precision Library platform, which includes NEObody™, SAFEbody®, and POWERbody™ technologies.
Adagene Inc. (Nasdaq: ADAG) has announced strategic board and management appointments to drive its growth in antibody-based therapies. Liu Yuwen joins as an independent board member, while Jiping Zha, M.D., Ph.D., and Dana Hu-Lowe, Ph.D., have been appointed as Executive Vice President of Clinical Development and Vice President of Global Product Team Leadership, respectively. These changes come as the company prepares to leverage its AI-powered antibody technology platform for rapid pipeline growth and capitalize on industry opportunities.
Adagene Inc. (Nasdaq: ADAG) announced the dosing of the first patient in a phase 1b/2 trial for its anti-CD137 agonist ADG106 combined with anti-CTLA-4 mAb ADG116, targeting advanced solid tumors. This trial aims to evaluate safety and tolerability of the innovative combination, addressing unmet needs in cancer therapies. Both ADG106 and ADG116 have shown strong safety profiles and early efficacy signals in previous trials. The study is expected to set a new precedent for combination therapies in oncology, aligning with Adagene's mission to advance antibody-based cancer treatments.
Adagene Inc. (Nasdaq: ADAG) has appointed Dr. David Gandara to its Scientific and Strategic Advisory Board. Dr. Gandara is known for his expertise in cancer drug development and biomarker strategies. He expressed enthusiasm for Adagene's potential in advancing immuno-oncology treatments. Adagene CEO Peter Luo highlighted Gandara's insights as valuable, especially concerning the trial of ADG106 in combination with Nivolumab for non-small cell lung cancer. Dr. Gandara's extensive credentials enhance Adagene's leadership in the immunotherapy field.
Adagene Inc. (Nasdaq: ADAG) has initiated a phase 1b/2 clinical trial for ADG106, an anti-CD137 agonist antibody combined with nivolumab for advanced non-small cell lung cancer (NSCLC) patients. The trial, conducted in Singapore, aims to evaluate safety, tolerability, and efficacy in 53 patients who have progressed after prior treatments. Dr. Peter Luo mentioned the trial's potential to address resistance to anti-PD-1 therapy. This development is crucial, given that metastatic NSCLC is a leading cause of cancer-related deaths worldwide.
Adagene Inc. (Nasdaq: ADAG) announced a $3 million milestone payment triggered by the successful nomination of lead SAFEbody candidates in collaboration with Exelixis. This milestone underscores the efficacy of Adagene's SAFEbody precision masking technology in developing antibody-drug conjugates. The collaboration also included an upfront payment of $11 million and eligibility for further commercialization milestones and royalties. Adagene's pipeline includes several clinical-stage programs, with ongoing trials validating its SAFEbody technology in treating cancer.
Adagene (Nasdaq: ADAG) presented preclinical data at the 63rd American Society of Hematology Annual Meeting, highlighting two promising programs: ADG153, an anti-CD47 monoclonal antibody, and ADG152, a CD20xCD3 bispecific T-cell engager. ADG153 demonstrated reduced hematologic toxicities and an 8-fold prolonged half-life, while ADG152 showcased enhanced therapeutic index with minimized cytokine release. These findings support advancing both candidates into clinical development, showcasing Adagene's commitment to innovative cancer immunotherapies and the strength of its AI-driven antibody platform.
Adagene Inc. has presented promising clinical data on its anti-CTLA-4 monoclonal antibody ADG116 and anti-CD137 agonist ADG106 at the ESMO-IO Congress 2021. ADG116 showed a strong safety profile and early efficacy signals in patients with advanced solid tumors, with a notable 22% tumor reduction in a pancreatic cancer patient. Additionally, ADG106 demonstrated significant synergy with toripalimab, enhancing immune activation. These findings reinforce Adagene's commitment to developing innovative antibody-based immunotherapies and advancing its clinical pipeline.
Adagene presented promising clinical data for its monoclonal antibodies, ADG116 and ADG106, at the ESMO-IO Congress 2021. The ongoing trial of ADG116 indicated a strong safety profile with early efficacy signals in treatment-resistant tumors. Key findings included a 22% reduction in tumor size for a pancreatic cancer patient and evidence of immune activation. ADG106 showed enhanced immune response when combined with toripalimab. The trials aim to advance these therapies targeting advanced solid tumors, reinforcing Adagene's commitment to innovative cancer treatments.
Adagene has received FDA clearance for the IND application to initiate the Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody, ADG116, in combination with pembrolizumab. The global study (ADG116-P001) will target advanced metastatic solid tumors and will commence in early 2022 across multiple sites in the U.S. and Asia Pacific. This trial aims to evaluate safety, tolerability, and preliminary efficacy. Additionally, the ongoing ADG116-1003 trial will explore ADG116 in combinations with other therapies.